Potent and selective 5-HT2A receptor antagonist (Ki values are 0.13, 4.55, 40, 62 and 1570 nM at 5-HT2A, α1, 5-HT2C, D2 and 5-HT1A respectively). Centrally active following systemic administration in vivo.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||8.96||20 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 447.95. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.23 mL||11.16 mL||22.32 mL|
|5 mM||0.45 mL||2.23 mL||4.46 mL|
|10 mM||0.22 mL||1.12 mL||2.23 mL|
|50 mM||0.04 mL||0.22 mL||0.45 mL|
References are publications that support the biological activity of the product.
Herth et al (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg.Med.Chem. 17 2989 PMID: 19329329
Kennett et al (1994) Evidence that 5-HT2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology 114 90 PMID: 7846211
Koenig et al (1987) Stimulation of corticosterone and β-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur.J.Pharmacol. 137 1 PMID: 2956114
Sietnick (1985) Involvement of 5-HT2 receptors in the LSD- and L-5-HTP-induced suppression of lordotic behavior in the female rat. J.Neural Transm. 61 65 PMID: 3872342
If you know of a relevant reference for Altanserin hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Altanserin hydrochloride, Altanserin hydrochloride supplier, 5-HT2A, receptor, antagonists, Serotonin, Receptors, 1809, Tocris Bioscience
2 Citations for Altanserin hydrochloride
Citations are publications that use Tocris products. Selected citations for Altanserin hydrochloride include:
Yu and Yamaguchi (2009) 5-HT2C-like receptors in the brain of Xenopus laevis initiate sex-typical fictive vocalizations. J Neurophysiol 102 752 PMID: 19474172
Niebert et al (2011) Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. Am J Physiol Regul Integr Comp Physiol 6 e21395 PMID: 21789169
Do you know of a great paper that uses Altanserin hydrochloride from Tocris? Please let us know.
Reviews for Altanserin hydrochloride
There are currently no reviews for this product. Be the first to review Altanserin hydrochloride and earn rewards!
Have you used Altanserin hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.